Search clinical trials for: SHR-1819

Total 1900 results

Kainos Medicine Inc.
Parexel

Recruiting

Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA)

Multiple System Atrophy

Korea, Republic of
Shengjing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR-A1811 Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

HER2-positive Breast Cancer

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Study of SHR-1501 Alone or in Combination With BCG in Subjects With NMIBC

High-risk NMIBC

China
Wuhan Union Hospital, China

Not yet recruiting

A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung Cancer

Limited-stage Small Cell Lung Cancer, LS-SCLC
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate SHR-1210 in Subjects With Advanced HCC

Hepatocellular Carcinoma Non-Resectable

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma

Hodgkin Lymphoma, Adult

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Carcinoma, Bronchogenic | Lung Disease | Respiratory Tract Disease | Respiratory Tract Neoplasms Nec | Neoplasm, Bronchial

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

SHR-1701 in Patients With Recurrent/Metastatic Scchn

Squamous Cell Carcinoma of Head and Neck

China
ModernaTX, Inc.

Active, not recruiting

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-Year-Old Healthy Adolescents and Adults

Epstein-Barr Virus Infection

United States
PegBio Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects

Obesity
argenx

Recruiting

A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants

Healthy Volunteers

Netherlands
PegBio Co., Ltd.

Completed

Continuous Multiple Dose PB-119 Injection in Health Volunteers

Type2 Diabetes Mellitus

China
Neuralstem Inc.

Completed

Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189

Depression

United States
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Relapsed or Advanced Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects

Advanced Solid Tumors

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Sention Therapeutics, LLC

Active, not recruiting

A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism

Hypothyroidism

United States
PegBio Co., Ltd.
Covance

Completed

Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM)

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.

Nasopharyngeal Carcinoma

China
Hangzhou Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Completed

Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer

Esophageal Neoplasms | Esophageal Diseases | Esophageal Squamous Cell Carcinoma

China
FAScinate Therapeutics Inc.
Parexel

Active, not recruiting

A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants With Parkinson's Disease

Parkinson Disease

United States
Kainos Medicine Inc.

Completed

Phase I, KM-819 in Healthy Subjects for Parkinson's Disease

Parkinson's Disease

Korea, Republic of
AbbVie

Completed

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Advanced Solid Tumors Cancer

United States, France, Japan, Puerto Rico, Spain, Taiwan
Nektar Therapeutics

Completed

Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain (SUMMIT-LTS)

Low Back Pain | Chronic Pain

United States
Hebei Medical University Fourth Hospital

Not yet recruiting

Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer

Breast Cancer
Shanghai Chest Hospital

Not yet recruiting

A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. (CAMFA-L)

NSCLC

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects

Breast Cancer | Solid Tumor | Gastrointestinal Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients

Ovarian Cancer

China
AbbVie

Terminated

A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer

Colorectal Cancer

United States
Amgen

Completed

Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Belgium, Canada, Denmark, Italy, Hungary, Germany, Switzerland, Netherlands, Australia, Russian Federation, Austria, France, United Kingdom, Czechia, Greece, Poland, Estonia, Latvia, Norway
Amgen

Completed

Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease

Crohn's Disease

United States, Canada, Denmark, Belgium, Hungary, Switzerland, Netherlands, Austria, Czechia, France, United Kingdom, Germany
Anchiano Therapeutics Israel Ltd.

Completed

Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer

Ovarian Cancer

Israel
Anchiano Therapeutics Israel Ltd.

Completed

Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer

Pancreatic Neoplasms

United States, Israel
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2+ Gastric Cancer

HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

China
Centaur Pharmaceuticals

Unknown

Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia

HIV Infections

United States
Fudan University
Shanghai Shen Kang Hospital Development Center

Recruiting

Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

Urinary Bladder Neoplasms | Immunotherapy

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer

Esophageal Cancer

China
Sun Yat-sen University

Active, not recruiting

PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma (DIPPER)

Nasopharyngeal Neoplasms

China
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy

Primary IgA Nephropathy

China
Peking Union Medical College Hospital

Not yet recruiting

SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer

Anlotinib | Advanced Esophageal Squamous Cell Cancer | SHR-1210
Fudan University

Active, not recruiting

Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY）

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors

Neoplasm Malignant | Tumor, Solid | Cancer, Metastatic

China
Clover Biopharmaceuticals AUS Pty Ltd

Recruiting

First-in-human Safety and Immunogenicity Study of SCB-1019 in Healthy Adults

Respiratory Syncytial Virus Infection

Australia
AbbVie

Completed

Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)

Human Immunodeficiency Virus (HIV)

United States, Puerto Rico
AbbVie

Terminated

SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers

Cancer

United States
InQpharm Group

Completed

Influence of IQPAS-119 on Post-Marathon Susceptibility to Infections and Others

Upper Respiratory Tract Symptoms

Germany
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.

Advanced Hepatocellular Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-A1403 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis

Moderate-to-severe Plaque Psoriasis

China

3

Subscribe